COVID-19 rapid evidence summary: angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in people with or at risk of COVID-19 – evidence summary (ES24)

Two retrospective observational studies found no increase in risk of developing COVID-19 or more severe disease in association with ACEI or ARB use. The studies were however of poor quality and subject to bias and confounding, so no robust conclusions can be drawn.

Source:

National Institute for Health and Care Excellence